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ABSTRACT
Objectives: The prevention and management of
venous thromboembolism (VTE) is often at variance
with guidelines. The CareTrack Australia (CTA) study
reported that appropriate care (in line with evidence-
based or consensus-based guidelines) is being
provided for VTE at just over half of eligible
encounters. The aim of this paper is to present and
discuss the detailed CTA findings for VTE as a
baseline for compliance with guidelines at a
population level.
Setting: The setting was 27 hospitals in 2 states of
Australia.
Participants: A sample of participants designed to be
representative of the Australian population was
recruited. Participants who had been admitted
overnight during 2009 and/or 2010 were eligible. Of
the 1154 CTA participants, 481(42%) were admitted
overnight to hospital at least once, comprising 751
admissions. There were 279 females (58%), and the
mean age was 64 years.
Primary and secondary outcome measures: The
primary measure was compliance with indicators of
appropriate care for VTE. The indicators were extracted
from Australian VTE clinical practice guidelines and
ratified by experts. Participants’ medical records from
2009 to 2010 were analysed for compliance with 38
VTE indicators.
Results: Of the 35 145 CTA encounters, 1078 (3%)
were eligible for scoring against VTE indicators. There
were 2–84 eligible encounters per indicator at 27
hospitals. Overall compliance with indicators for VTE
was 51%, and ranged from 34% to 64% for
aggregated sets of indicators.
Conclusions: The prevention and management of VTE
was appropriate for only half of the at-risk patients in
our sample; this provides a baseline for tracking
progress nationally. There is a need for national and,
ideally, international agreement on clinical standards,
indicators and tools to guide, document and monitor
care for VTE, and for measures to increase their
uptake, particularly where deficiencies have been
identified.
INTRODUCTION
Each year in Australia about 1 in every 1000
people develop a ﬁrst episode of venous
thromboembolism (VTE), manifesting as
deep venous thrombosis (DVT) and/or pul-
monary embolism (PE).1 2 This amounts to
about 20 000 cases, of which 80% occur
during or soon after an admission to hos-
pital.1 2 Including loss of productivity, total
costs amount to well over $A1 billion per
year.3
There is evidence that the appropriate use
of pharmacological and mechanical prophy-
laxis in orthopaedic, general surgical and
medical patients can reduce the incidence of
VTE,4–6 although a recent paper has ques-
tioned use of pharmacological prophylaxis in
lower risk medical patients.7 Clinical practice
guidelines (CPGs) have been developed, in
Australia8 9 and elsewhere,10 11 to prevent
VTE and to standardise the management of
DVT and PE. Several initiatives have been
undertaken to promote and facilitate their
uptake, including implementation guides,12
templates,13 learning modules,14 hospital
Strengths and limitations of this study
▪ The study is designed to be representative of the
Australian population rather than a convenience-
based or purposive-based sample.
▪ The review of medical records, while costly and
difficult, allowed compliance to be measured in a
real-world setting.
▪ Numbers of participants and/or eligible encoun-
ters are low for some indicators.
▪ There was a high rate of attrition of potential par-
ticipants and several sources of possible bias.
However, weighting using two methods and five
different options made no significant difference
to the compliance percentage.
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medication self-assessments15 and patient information
pamphlets.16 However, despite these initiatives and the
considerable harm from VTE, much of the care pro-
vided for VTE is not in line with CPGs17 in both the
developed18 and developing worlds.19
As healthcare is facing an affordability crisis, there is
an urgent need to move towards being able to monitor
the appropriateness of care (care in line with evidence-
based or consensus-based guidelines).20 The CareTrack
Australia (CTA) study was designed to establish baseline
estimates of the appropriateness of care delivered, at a
population level, by a range of practitioners in real-world
settings, and to determine what would be needed to
monitor the ongoing appropriateness of care.21 CTA
showed that adult Australians received appropriate care
for 22 common conditions at 57% of eligible healthcare
encounters during 2009 and 2010; VTE compliance was
reported at 58%.22 The aim of this paper is to present
and discuss the detailed CTA ﬁndings for VTE as a base-
line for compliance with guidelines at a population
level, from which to track progress resulting from future
interventions.
METHODS
The CTA methods have been described in detail else-
where.21 22 Some aspects of relevance to VTE are sum-
marised here.
Development and ratification of indicators
An initial list of 15 indicators (with 54 subcriteria) was
sourced from recommendations within the National
Health and Medical Research Council guidelines8 9 and
sent to three practising specialist haematologists who
were Heads of Departments, asking them to comment
on and rate each on a scale of 1–9 for appropriateness23
in the Australian context during 2009 and 2010. A
two-round review process was used and a formal process
was employed for managing discrepancies between spe-
cialists.21 Opinions of other specialists were not can-
vassed for logistical reasons. This resulted in 39
indicators being accepted as appropriate: 31 relating to
pharmacological and mechanical prophylaxis and eight
to risk assessment, discharge care and management of
DVT or PE (see table 1).
Recruitment of participants and healthcare providers
A sample designed to be representative of the Australian
adult population was used. Households were randomly
selected from a phone directory (the Telstra White
Pages) from deﬁned regions within New South Wales
and South Australia and contacted using a
Computer-Assisted Telephone Interview (CATI).21 22
One adult was randomly selected from each household
and was asked to participate. Those who agreed were
sent a mail package containing information about the
study and a consent form to allow access to their
medical records. Participants who provided consent
were called back and asked if they had been admitted
overnight to a hospital or had one or more of the CTA
conditions, and which healthcare providers they had
seen for these in 2009 and 2010. Hospitals identiﬁed by
the participants were contacted and asked to provide
their consent for medical record access.22
Review of medical records
Medical record reviews were undertaken for the 1154
consenting participants whose healthcare providers had
also provided consent. Healthcare encounters were
deemed eligible for scoring of VTE indicators if a par-
ticipant had been admitted overnight during 2009 and/
or 2010.
Experienced registered nurses were recruited and
trained as surveyors to conduct the medical record
reviews using a web-based tool for onsite encrypted data
collection. They were provided with formal training and
received a manual with detailed criteria for inclusion,
exclusion and scoring of indicators.
Estimates of compliance were measured as the per-
centage of eligible encounters for the VTE indicators
that were answered ‘yes’.21 22 The inclusion criteria for
the indicators for VTE prophylaxis were speciﬁc to par-
ticular types of surgery (eg, hip fracture surgery or
abdominal surgery) or medical conditions (eg, decom-
pensated cardiac failure or acute on chronic lung
disease).8 9 As the CTA study was designed to measure
the overall appropriateness of the healthcare delivered
for 22 conditions and was not powered for signiﬁcant
results at indicator level, the number of eligible encoun-
ters for many indicators was low. To address this, indica-
tors were aggregated into broader, clinically meaningful
categories. For example, orthopaedic conditions with
pharmacological prophylaxis (indicators 45–48) were
grouped and included hip arthroplasty, hip fracture
surgery, knee arthroplasty and lower limb fractures (see
table 1).
Data relating to documentation of VTE risk assessment
(indicator 42) was not included in the analysis reported
here, as a review of surveyor practices revealed that some
had assumed that a risk assessment had been carried
out whenever appropriate prophylaxis had been pre-
scribed, whether or not explicit documentation of an
assessment was found. This was in breach of the criteria
for this indicator, and these data were thus excluded.
Statistical analysis
Mean compliance and associated 95% CIs (using a
modiﬁed version of the Clopper-Pearson (exact)
method) were obtained using the SURVEYFREQ proced-
ure in SAS V.9.3 for Windows (SAS Institute, Cary, North
Carolina, USA). To address biases arising from the study
design (including adjustment for non-response), two dif-
ferent weighting options and ﬁve versions of weights
(three based on approaches used in the similar US
study23) were used to generate weighted estimates of
compliances. These were not signiﬁcantly different to
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Table 1 CTA indicators (and aggregated sets of indicators) by compliance
Indicator
number Indicator and sets of indicators
Eligible
encounters
(N)
Compliant
encounters
(N)
Compliance*
(%)
95%
confidence
limits† (%)
45–48 Patients undergoing certain orthopaedic
procedures or care received appropriate
pharmacological anticoagulant therapy
55 34 62 48–75
45 Patients who had a hip arthroplasty have received
anticoagulant therapy for up to 35 days‡
22 12 Insufficient data to report
46 Patients who had hip fracture surgery have received
anticoagulant therapies for up to 35 days§
2 2 Insufficient data to report
47 Patients who had a knee arthroplasty received
anticoagulant therapies for up to 28 days¶
24 16 Insufficient data to report
48 Patients who had a lower limb fracture received
anticoagulant therapies for at least 5 days or until
fully mobile§
7 4 Insufficient data to report
62, 68–70,
73–75
Patients undergoing certain orthopaedic
procedures or care received appropriate
mechanical anticoagulant therapy
104 49 47 37–57
62 Patients having a total hip replacement have been
prescribed graduation compression stockings
20 19 Insufficient data to report
68 Patients having a total hip replacement have been
prescribed an intermittent pneumatic compression
device
18 11 Insufficient data to report
69 Patients having hip fracture surgery have been
prescribed an intermittent pneumatic compression
device
3 1 Insufficient data to report
70 Patients having a total knee replacement have been
prescribed an intermittent pneumatic compression
device
21 15 Insufficient data to report
73 Patients having a total hip replacement have been
prescribed a foot pump
18 1 Insufficient data to report
74 Patients having a total knee replacement have been
prescribed a foot pump
22 2 Insufficient data to report
75 Patients having hip fracture surgery have been
prescribed a foot pump
2 0 Insufficient data to report
49–54 Patients undergoing non-orthopaedic surgical
procedures (general, gynaecological, abdominal,
cardiac, thoracic or vascular, trauma or spinal
surgery) or who had cancer and underwent
surgery received appropriate pharmacological
anticoagulant therapy
226 76 34 27–41
49 Patients who had a general surgical procedure
received anticoagulant therapies (unless
contraindicated) until hospital discharge or fully
mobile**
55 19 35 22–49
50 Patients who had gynaecological surgery received
anticoagulant therapies (unless contraindicated) until
hospital discharge or fully mobile**
26 5 Insufficient data to report
51 Patients who had abdominal surgery received
anticoagulant therapies (unless contraindicated) until
hospital discharge or fully mobile**
61 29 48 18–78
52 Patients who had cardiac, thoracic or vascular
surgery received anticoagulant therapies (unless
contraindicated) until hospital discharge or fully
mobile**
31 12 39 16–66
53 Patients who had trauma or spinal surgery received
anticoagulant therapies started after primary
haemostasis was established (unless
contraindicated) until hospital discharge or fully
mobile**
18 0 Insufficient data to report
Continued
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Table 1 Continued
Indicator
number Indicator and sets of indicators
Eligible
encounters
(N)
Compliant
encounters
(N)
Compliance*
(%)
95%
confidence
limits† (%)
54 Patients who have cancer that underwent surgery
received one of the following anticoagulant therapies
(unless contraindicated) until hospital discharge or
fully mobile**
35 11 31 5–74
63–67,
71–72
Patients undergoing non-orthopaedic surgical
procedures received appropriate mechanical
anticoagulant therapy
294 176 60 52–67
63 Patients having general surgery have been
prescribed graduated compression stockings
72 63 88 78–94
64 Patients having gynaecological surgery have been
prescribed graduation compression stockings
28 21 Insufficient data to report
65 Patients having abdominal surgery have been
prescribed graduation compression stockings
66 48 73 46–91
66 Patients having cardiac, thoracic or vascular surgery
have been prescribed graduation compression
stockings
52 17 33 2–85
67 Patients having neurosurgery have been prescribed
graduation compression stockings
13 11 Insufficient data to report
71 Patients having cardiac, thoracic or vascular surgery
have been prescribed an intermittent pneumatic
compression device
50 7 14 2–41
72 Patients having neurosurgery have been prescribed
an intermittent pneumatic compression devices
13 9 Insufficient data to report
55–61 Medical patients admitted to hospital with certain
conditions received appropriate pharmacological
anticoagulant therapy
167 77 46 36–57
55 Medical patients admitted to hospital with ischaemic
stroke received anticoagulant therapies until
resolution of the acute medical illness or until
hospital discharge††
5 1 Insufficient data to report
56 Medical patients admitted to hospital with myocardial
infarct (where full anticoagulant is not in use)
received anticoagulant therapies until resolution of
the acute medical illness or until hospital
discharge††
15 6 Insufficient data to report
57 General medical patients admitted to hospital
assessed as being at risk of VTE received
anticoagulant therapies until resolution of the acute
medical illness or until hospital discharge††
84 43 51 40–62
58 Medical patients admitted to hospital with active
cancer received anticoagulant therapies until
resolution of the acute medical illness or until
hospital discharge††
23 8 Insufficient data to report
59 Medical patients admitted to hospital with
decompensated cardiac failure received
anticoagulant therapies until resolution of the acute
medical illness or until hospital discharge††
7 3 Insufficient data to report
60 Medical patients admitted to hospital with acute on
chronic lung disease received anticoagulant
therapies until resolution of the acute medical illness
or until hospital discharge††
31 15 48 30–67
61 Medical patients admitted to hospital with acute on
chronic inflammatory disease received anticoagulant
therapies until resolution of the acute medical illness
or until hospital discharge††
2 1 Insufficient data to report
Continued
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unweighted compliances overall or for any condition
(including VTE). Hence, unweighted compliances were
used for this analysis.22 Appendix 2 of the CTA study
outlines the detailed methodology and overall results.22
RESULTS
Of the 1154 CTA participants, 481(42%) were admitted
overnight to hospital at least once, with a total of 751
admissions eligible for assessment against the VTE indi-
cators. There were 279 females (58%), and the mean
age was 64 years (6% were aged 18–39, 17% 40–54, 56%
55–74 and 21% were over 70 years of age).
Of the 35 145 CTA encounters (with duplicates and
the risk indicator removed), 1078 (3%) were eligible for
scoring against VTE indicators; the number of eligible
encounters per indicator ranged from 2 to 84. Records
were reviewed at 33 hospitals, with 27 having eligible
encounters. Eight of the hospitals had 50 or more eli-
gible encounters.
Overall compliance with the VTE indicators was 51%
(95% CI 47% to 54%), with results for aggregated sets
Table 1 Continued
Indicator
number Indicator and sets of indicators
Eligible
encounters
(N)
Compliant
encounters
(N)
Compliance*
(%)
95%
confidence
limits† (%)
76–80 Patients with suspected PE/DVT were managed
with appropriate investigations, or had
anticoagulant therapy started as soon as
clinically suspected; or if PE/DVT confirmed,
were managed appropriately
89 57 64 51–76
76 Patients with a suspected DVT had a venous duplex
ultrasound performed
12 10 Insufficient data to report
77 Patients with a suspected PE had investigations
performed‡‡
21 17 Insufficient data to report
78 Patients with a suspected DVT or PE where
ultrasound was delayed, had anticoagulant therapy
started (unless contraindicated) as soon as clinically
suspected
10 8 Insufficient data to report
79 Patients with a confirmed DVT/PE received
anticoagulant therapies§§
6 3 Insufficient data to report
80 Patients who were administered heparin therapy had
it continued until the INR had been therapeutic for
48 h (INR range 2.0–3.0)
40 19 48 26–70
Patients discharged on anticoagulant therapy have an
appropriate documented care plan including details on the
intended duration of treatment AND a review date¶¶
70 32 46 31–61
43 Patients who are discharged on anticoagulant
therapy have a documented care plan that includes
details on the intended duration of treatment
73 43 59 46–71
44 Patients who are discharged on anticoagulant
therapy have a documented care plan that includes a
review date
70 35 50 29–71
Bold typeface indicates the aggregated indicators.
*Percentage compliance calculated as the number of compliant encounters/number of eligible encounters ×100.
†Compliance and per cent of compliance were not calculated for <30 encounters.
‡Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 u three times a day; fondiparinux 2.5 mg/day (started 6–8 h postoperatively);
rivaroxaban (orally); dabigatran (orally).
§Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 u three times a day; fondiparinux 2.5 mg/day (started 6–8 h postoperativey).
¶Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 u three times a day; fondiparinux 2.5 mg/day (started 6–8 h postoperatively);
rivaroxaban(orally); dabigatran (orally).
**Enoxaparin 20 mg/day; dalteparin 2500 U/day.
††Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 U two times or three times a day; assumed implicit and explicit risk
assessments included.
‡‡One of: ventilation perfusion scan; CT angiography; pulmonary angiography.
§§Heparin administered together with warfarin for at least 5 days; unfractionated heparin intravenous (APTT) or subcutaneous (dose/kg);
LMWH subcutaneously at least once daily.
¶¶Compliance for this aggregated indicator was both indicators 43 and 44 were compliant for a participant in an episode of hospitalisation. In
other aggregated indicators, compliance was measured by adding each individual encounter as each episode of hospitalisation was an
independent event.
APTT, activated partial thromboplastin time; DVT, deep venous thrombosis; INR, international normalised ratio; LDUH, low-dose
unfractionated heparin; LMWH, low molecular weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism.
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of indicators ranging from 34% to 64% (table 1).
Omission of the risk assessment indicator from the
overall score reduced compliance from the 58%
reported originally22 to the 51% reported here. For the
eight hospitals with 50 or more eligible encounters,
compliance ranged from 45% to 70%.
DISCUSSION
Our analysis of CTA data has shown that a sample of 481
Australian adults in 27 hospitals received appropriate
care for VTE during 2009 and 2010 at only 51% of eli-
gible healthcare encounters, in spite of considerable
efforts to promote and facilitate the uptake of CPGs in
Australia.12–16 Thus, despite the prevalence, cost, mor-
bidity and mortality associated with VTE and PE, prophy-
laxis and treatment are still in line with CPGs only half
the time. This continues to be a problem in both the
developed and developing worlds.17–19
CTA patients who had surgery received appropriate
pharmacological or mechanical anticoagulant therapy
on only 39% and 57% of occasions, respectively (aggre-
gations from table 1). The ENDORSE study, a multi-
national cross-sectional survey, also examined the
proportion of at-risk patients who received effective
prophylaxis.17 It found, for 804 patients from eight
Australian hospitals studied in 2006–2007, that 82% of
at-risk surgical patients received appropriate prophylaxis.
This study did not separate pharmacological and mech-
anical prophylaxis.17 Baseline (preintervention) com-
pliances for surgical patients were also higher than CTA
compliances in two single hospital studies (65% and
74% for pharmacological prophylaxis and 89% and 64%
for mechanical prophylaxis).24 25 Possible reasons for
the lower CTA compliances are that CTA was a
population-based study at 27 hospitals which were effect-
ively randomly selected, while ENDORSE mainly col-
lected data from prominent teaching hospitals, and the
two single hospital studies were about to start an inter-
vention for VTE prophylaxis, and had possibly raised
awareness of the problem.
In contrast, the CTA compliance for at-risk medical
patients at 46% (aggregations from table 1) was similar
to those in the eight Australian ENDORSE hospitals and
a regional hospital (51% and 64%, respectively).17 25
Lower compliances for medical than surgical patients in
the ENDORSE study and the regional hospital are con-
sistent with the more complex indications in medical
patients, and have been noted elsewhere.26 No equiva-
lent Australian studies could be found for indicators
associated with management of suspected or conﬁrmed
DVT or PE (CTA compliance 64%), or patients with a
documented discharge plan and a date for cessation of
treatment (CTA compliance 46%), but it would seem
reasonable to conclude that both of these areas of prac-
tice also require attention.
The risk assessment indicator was studied in two
Australian single-hospital studies which both found 0%
compliance at the preintervention stage, with modest
postintervention compliances of 28% and 36%.24 27
The poor compliances with VTE indicators in
Australia are consistent with the lack of a system-wide
approach. Compliance measures or outcomes are not
publicly reported at hospital level,28 VTE is not
included in national standards,29 nor is it a national
healthcare goal.30 Australian clinicians have identiﬁed
that setting agreement on clinical guidelines and stan-
dards (agreement on risk categories, risk assessment
tools, mandatory actions and protocols, provision of
summaries), decision-support tools, and reporting
results are enablers to delivering appropriate VTE
care.31 32 The fact that compliance ranged from 45%
to 70% between hospitals suggests that some facilities
are faring better than others at managing VTE
appropriately.
Strengths and weaknesses
The key strength of the CTA study is that it is designed
to be representative of the Australian population to min-
imise selection bias, rather than a convenience-based or
purposive-based sample. However, an unavoidable conse-
quence of this strategy, coupled with ﬁnite research
funds, is that the numbers of participants and/or eli-
gible encounters are low for some indicators; 25 of 38
had insufﬁcient data to report. Findings for these must
be disregarded or interpreted with caution. The review
of medical records, while costly and difﬁcult, allowed
compliance to be measured in a real-world setting and
avoided the limitations inherent in asking healthcare
providers to respond to clinical vignettes33 34 or ques-
tionnaires.35 Errors arising from measurement (informa-
tion bias) were within acceptable limits for implicit
review.36–38 Accordingly CTA provides some baseline esti-
mates for compliance against which progress on the pro-
vision of appropriate care for VTE could be compared
and tracked.
The approach used was associated with a high rate of
attrition of potential participants and several other
sources of possible bias. Although it was not logistically
feasible to design sampling so as to eliminate all possible
confounders (confusion bias) or have the sample
characteristics to exactly match the Australian popula-
tion, weighting using two methods and ﬁve different
options made no signiﬁcant difference to the overall
compliance percentage, or that for VTE;22 this is consist-
ent with providers not altering their clinical practices for
patients of different ages, gender, or socioeconomic or
health literacy status.
Commentators have raised issues with respect to the
levels of evidence for and choice of indicators, effects of
comorbidities, inter-rater reliability and the possibility of
care having been provided but not recorded.36 37 These
have all been addressed:22 38 compliance was shown to
be no different for consensus-based and evidence-based
recommendations; the CTA indicators were designed to
be clinically relevant but not affected by comorbidities;
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inter-rater reliability was moderate, but was in line with
other studies using implicit medical record review;38 and
the effect on overall compliance of care received but not
documented is thought to be no more than 10%.23 39 40
CONCLUSION
Our analysis of the VTE indicators from the CTA study
show that compliance is modest at 51%, despite
resources and guidelines being available, and the high
associated cost and burden of disease. This is consistent
with the lack of a system-wide focus on VTE in Australia
as is the case in most of the rest of the world. In line
with recommendations arising from the overall CTA
study and feedback from clinicians, the challenge is to
now move towards agreement on national clinical stan-
dards and on the development of indicators and tools to
guide, document and monitor the appropriateness of
care for VTE. An inclusive, national wiki-based process
for achieving this has been proposed.20 VTE data could
then be monitored at hospital level and the data aggre-
gated at national and, potentially at international levels
to track progress and inform policy.
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